| Drug NDC: | 43857-0453 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Vax |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Baptisia Tinctoria, Echinacea (angustifolia), Tabebuia Impetiginosa, Trifolium Pratense, Arnica Montana, Calendula Officinalis, Chelidonium Majus, Leptandra Virginica, Ligusticum Porteri, Lomatium Dissectum, Myrrha, Nasturtium Aquaticum, Phytolacca Decandra, Taraxacum Officinale, Trigonella Foenum-graecum, Urtica Dioica, Hydrastis Canadensis, Astragalus Membranaceus, Propolis, Glandula Suprarenalis Suis, Thymus (suis), Arsenicum Album, Belladonna, Chamomilla, Lycopodium Clavatum, Rhus Tox, Silicea, |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Bioactive Nutritional, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ANTIMONY TRISULFIDE - 30 [hp_X]/mL ARNICA MONTANA - 4 [hp_X]/mL ARSENIC TRIOXIDE - 12 [hp_X]/mL ASTRAGALUS PROPINQUUS ROOT - 6 [hp_X]/mL ATROPA BELLADONNA - 12 [hp_X]/mL BAPTISIA TINCTORIA - 3 [hp_X]/mL BORDETELLA PERTUSSIS - 30 [hp_C]/mL CALENDULA OFFICINALIS FLOWERING TOP - 4 [hp_X]/mL CHAMOMILE - 12 [hp_X]/mL CHELIDONIUM MAJUS - 4 [hp_X]/mL Load more... ECHINACEA ANGUSTIFOLIA - 3 [hp_X]/mL FENUGREEK SEED - 4 [hp_X]/mL GOLDENSEAL - 5 [hp_X]/mL LIGUSTICUM PORTERI ROOT - 4 [hp_X]/mL LOMATIUM DISSECTUM ROOT - 4 [hp_X]/mL LYCOPODIUM CLAVATUM SPORE - 12 [hp_X]/mL MYRRH - 4 [hp_X]/mL NASTURTIUM OFFICINALE - 4 [hp_X]/mL PHYTOLACCA AMERICANA ROOT - 4 [hp_X]/mL PROPOLIS WAX - 6 [hp_X]/mL SILICON DIOXIDE - 30 [hp_X]/mL SUS SCROFA ADRENAL GLAND - 8 [hp_X]/mL SUS SCROFA THYMUS - 8 [hp_X]/mL TABEBUIA IMPETIGINOSA BARK - 3 [hp_X]/mL TARAXACUM OFFICINALE - 4 [hp_X]/mL TETANUS TOXIN - 30 [hp_C]/mL THIMEROSAL - 30 [hp_C]/mL THUJA OCCIDENTALIS LEAFY TWIG - 30 [hp_X]/mL TOXICODENDRON PUBESCENS LEAF - 12 [hp_X]/mL TRIFOLIUM PRATENSE FLOWER - 3 [hp_X]/mL URTICA DIOICA - 4 [hp_X]/mL VERONICASTRUM VIRGINICUM ROOT - 4 [hp_X]/mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 20 Jul, 2017 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 12 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | BioActive Nutritional, Inc. |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000185508 N0000175629 N0000184306 M0000728 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | F79059A38U O80TY208ZW S7V92P67HO 922OP8YUPF WQZ3G9PF0H 5K1UO2888Y 2QNL82089R 18E7415PXQ FGL3685T2X 7E889U5RNN Load more... VB06AV5US8 654825W09Z ZW3Z11D0JV 81FGO4H42J 5329928G5N C88X29Y479 JC71GJ1F3L YH89GMV676 11E6VI8VEG 6Y8XYV2NOF ETJ7Z6XBU4 398IYQ16YV 7B69B0BD62 6GLA1946WX 39981FM375 RS7296A9LB 2225PI3MOV 1NT28V9397 6IO182RP7A 4JS0838828 710FLW4U46 M2O62YTN42 |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class EPC: | Standardized Chemical Allergen [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Increased Histamine Release [PE] Cell-mediated Immunity [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Allergens [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 43857-0453-1 | 30 mL in 1 BOTTLE, DROPPER (43857-0453-1) | 20 Jul, 2017 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.